Overview of Cortafan

Property	Description
Active Ingredients	Attapulgite, Nifuroxazide
Form	Oral Capsules or Oral Suspension
Pharmacological Class	Intestinal Adsorbent and Intestinal Anti-infective
Common Use	Management of acute diarrhea and associated symptoms
Origin	Combination of a natural mineral and a synthetic compound

Cortafan: Definition, Pharmacological Class, and General Purpose

Cortafan is a fixed-dose combination product classified as both an Intestinal Adsorbent and an Intestinal Anti-infective, providing a dual-approach strategy against acute gastrointestinal disturbances. The medicine is designed to target both the physical symptoms and a potential localized bacterial cause, making it a comprehensive choice for managing diarrhea. The anti-infective component, Nifuroxazide, belongs to the Nitrofuran derivative group. This classification indicates that the active substance is primarily used for the control of local gut infections, which separates it from systemic antibiotics.

What are the Active Ingredients in Cortafan?

The two active ingredients in Cortafan are Attapulgite and Nifuroxazide. Attapulgite is a natural-origin mineral characterized by its high capacity to physically bind substances within the digestive tract. This property defines its role as the adsorbent component in stabilizing fluid balance in the gut. Nifuroxazide is a synthetic organic compound providing the antibacterial action. Cortafan is designed for Oral consumption and is supplied in forms such as Oral capsules or a liquid Oral suspension, making it suitable for both adults and certain pediatric patients, depending on the specific formulation.

How Does Cortafan Work as a Dual-Action Medicine?

Cortafan functions through two complementary principles: Adsorption and Localized Anti-Infection, both confined to the gut lumen. The Attapulgite component exerts a physical binding action, absorbing excess water, toxins, and acids, which helps reduce the volume and fluidity of bowel movements. Concurrently, Nifuroxazide works locally to inhibit key bacterial enzymes, leading to bactericidal activity against susceptible microorganisms. As a localized antibacterial agent, Nifuroxazide is non-absorbable, with its action confined to the intestines. This ensures the medicine directly addresses the infectious component while minimizing systemic impact.

What side effects are possible with Cortafan?

Possible Side Effects and Safety Information

The safety profile of Cortafan, which combines an Intestinal Adsorbent (Attapulgite) and an Intestinal Anti-infective (Nifuroxazide), is derived from the adverse reactions officially documented for its components. Adverse effects are classified by their frequency and the body system affected, according to standard regulatory terminology.

Documented Adverse Reactions and Frequencies

Adverse reactions are formally grouped into System-Organ Classes, with primary focus on Gastrointestinal and Immune System Disorders.

Classification	System-Organ Class	Examples of Documented Reactions
Common	Gastrointestinal Disorders	Constipation
Uncommon	Gastrointestinal Disorders	Nausea, Vomiting, Abdominal pain
Rare	Skin and Immune System Disorders	Rash, Urticaria (hives), Pruritus (itching)

Serious adverse reactions are reported as rare or very rare. These include severe hypersensitivity reactions, such as Angioedema and the potential for Anaphylaxis, which are documented risks associated with the anti-infective component.

Population and Exposure-Related Safety Notes

The regulatory safety profile includes specific constraints regarding its use. The product is officially contraindicated in patients with a known hypersensitivity to its active substances or in the presence of existing intestinal obstruction, due to the physical properties of Attapulgite.

Population-specific safety considerations are noted for pediatric patients, where use may be contraindicated in certain age groups (e.g., infants under two years) as stated in official labeling. Additionally, caution is noted in individuals with severe renal impairment.

The label notes that the risk of constipation may increase with the duration of treatment, a pattern observed with intestinal adsorbents. Furthermore, the adsorbent component may reduce the absorption of other concomitantly administered oral medicines, a documented safety limitation.

Overdose and Emergency Response

Overdose and When to Seek Help: Regulatory Information

Overdose with Cortafan is primarily defined by the risks associated with excessive exposure to its adsorbent component. The official regulatory labeling indicates that high doses or prolonged use of the adsorbent component (Attapulgite) may lead to severe manifestations, including severe constipation or intestinal impaction. This potential for intestinal obstruction represents the most serious life-threatening outcome documented in the medicine’s regulatory profile, while official documents indicate a lack of specific clinical data concerning Nifuroxazide overdose.

Mandated Urgent Actions:

In any event of suspected overdose, official guidance mandates that individuals must contact a Poison Control Center immediately. Immediate medical attention must be sought if signs of severe complications are experienced. Urgent medical care is explicitly required upon the onset of symptoms indicative of bowel obstruction, such as persistent vomiting, abdominal pain, or an inability to pass gas or stool.

Management and Specific Considerations:

Management of a Cortafan overdose involves symptomatic and supportive treatment, including necessary patient observation. Regulatory documents confirm that no specific antidote is known for this medicine. Furthermore, it is officially noted that elderly or debilitated patients are at an increased risk of developing impaction or obstruction due to the mechanical action of the adsorbent component.

Therapeutic Uses of Cortafan

What Cortafan Treats: Main Uses and Benefits

The therapeutic approach is relevant for managing symptoms related to localized microbial states and physical discomfort. This approach is relevant across conditions presenting with acute episodes of diarrhea. Within this context, the adsorbent component is relevant for easing symptoms related to intestinal output abnormalities.

Cortafan is commonly used to help with managing acute diarrheal symptoms, including symptoms related to physical discomfort such as loose or watery stools and high frequency of defecation. The combination is applied in addressing conditions where symptoms may intensify temporarily due to localized microbial states, such as in traveler's diarrhea and acute bacterial enteritis. This benefit helps manage symptoms related to inflammatory or irritative states while simultaneously assisting with movement toward stool consistency improvement.

“The product is relevant across acute therapeutic contexts where symptoms related to physical discomfort and localized irritative states are both experienced.”

The combined therapeutic action contributes to improved comfort by supporting the body in managing symptoms related to systemic imbalance, such as excessive fluid loss, and reducing symptoms related to physical discomfort. This is relevant across adult and pediatric patient groups (in specific formulations), where supportive relief helps patients cope more steadily with symptom fluctuations and assists with maintaining functional stability.

Quick Fact: Relief for Acute Diarrhea
Supports symptomatic management by addressing stool consistency and frequency.

Eligibility and Restrictions for Use

Official Eligibility for Cortafan

The use of Cortafan is strictly defined by regulatory eligibility rules that specify approved populations and absolute exclusions based on age, physiological state, and existing medical conditions. The following criteria are explicitly stated in government labeling:

Eligibility Status	Defined Population/Condition
Contraindicated	Individuals with known hypersensitivity to Nifuroxazide, Attapulgite, or nitrofuran derivatives.
Contraindicated	Children under 2 years of age, including new-borns and premature infants.
Contraindicated	Patients with known or suspected intestinal obstruction, impaction, or severe constipation.
Use Allowed	Adults and children aged 2 years and older (in appropriate formulations).
Not Recommended	Use in pregnancy (as a regulatory precaution); use in lactation is possible only for short-term treatment.
Use with Caution	Patients with compromised renal or hepatic function; older adults or debilitated patients.

Regulatory documentation defines that use must be avoided in populations with pre-existing bowel obstruction risks due to the adsorbent component. Furthermore, the label requires special caution for patients with reduced organ function and strictly prohibits use in infants under two years of age.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The officially documented interaction profile for Cortafan is primarily structured by the non-systemic, physico-chemical properties of its active component, Attapulgite. This substance acts as an intestinal adsorbent, meaning its physical binding capacity can interfere with the absorption of other orally administered products.

Official Regulatory Interaction Profile

Property	Official Regulatory Statement
Mechanistic basis of interactions	Physico-chemical interaction resulting from the adsorption capacity of Attapulgite, leading to reduced gastrointestinal absorption of co-administered substances.
Medicinal product categories	Oral Antibiotics (e.g., Quinolones, Tetracyclines), Oral Anticoagulants, and Oral Mineral Supplements.
Timing-based interaction rules	Mandatory separation of dosing is required for all other oral medicinal products and supplements. Regulatory caution typically advises administration two to three hours before or after Cortafan.
Population-specific interaction notes	The risk of physical binding consequences (e.g., impaction) may be increased in the elderly and debilitated patients.

Connection to the overall interaction profile

The regulatory profile defines a pharmacokinetic interaction where the non-systemic Attapulgite component reduces the exposure of other orally administered substances. This effect is managed by a clear procedural constraint requiring the mandatory timing separation of Cortafan from other oral medicines to maintain their intended efficacy, as stated in government drug cautions.

Mechanism of Action

How Cortafan Works: Mechanism of Action

Cortafan's functional characteristics are derived from two distinct, highly localized, and non-systemic mechanistic domains that combine a physical binding process with a targeted anti-infective action within the gastrointestinal (GI) lumen.

Physical Adsorption and Intestinal Fluid Dynamics

The mineral component acts through non-selective surface adsorption, primarily targeting excess water and various luminal irritants such as bacterial toxins. This physical mechanism affects intestinal fluid dynamics by increasing the bulk and reducing the fluidity of the contents, resulting in the modification of stool rheology without modulating human receptors or enzyme systems.

Localized Bactericidal Bioactivation

The anti-infective component relies on bacterial nitroreductase enzymes for localized bioactivation within susceptible pathogens. This process generates highly reactive intermediates that disrupt essential bacterial macromolecules (DNA, RNA, and metabolic enzymes), leading to a bactericidal effect that results in a reduction of the pathogenic bacterial population.

Functional Mechanistic Complementarity

These mechanisms operate in parallel: the physical adsorption contributes to the regulation of intraluminal fluid volume, while the bioactivation establishes a process for the elimination of pathogenic bacteria. This functional complementarity defines the compound's composite physiological action by acting on both the physical fluid content and the microbial population.

Dosage and Administration Information

The administration of Cortafan (Attapulgite and Nifuroxazide) is characterized by its role as a short-course, locally acting oral medicine. Use is governed by frequency and duration parameters for intestinal adsorbents and anti-infectives.

Administration Guidelines

Feature	Description
Route of Administration	Exclusively the Oral route, available as capsules and liquid suspension.
Dosing Schedule	A fixed unit dose is taken on a fixed time schedule.
Frequency and Duration	Dosing is typically three to four times daily for a mandated short course, commonly limited to three days.
Timing	The medicine is generally instructed to be taken with meals or food.
Preparation	The Oral Suspension must be shaken well immediately prior to measuring the dose to ensure uniform dispersion.
Special Conditions	Capsules must be swallowed whole with water. The duration of therapy is strictly limited and must not be exceeded.

Population Rules

The Oral Suspension is the designated dosage form for use in pediatric patients, where dosing is calculated specifically based on the child’s age group or body weight.
There are no explicit dose adjustments provided for older adults or patients with hepatic or renal impairment, maintaining strict adherence to the mandated short duration.

This structured approach dictates the precise parameters for the correct administration of the medicine.

Recent Clinical Evidence

Cortafan: Recent Clinical Evidence

This section summarizes the structure of the clinical research conducted for Cortafan, including the types of studies available, the patient populations examined, and key areas where scientific data is still developing, strictly adhering to findings described in authoritative governmental or peer-reviewed scientific sources.

Evidence for use in Acute Diarrhea and Gastrointestinal Disturbances

The research base includes Randomized Controlled Trials (RCTs), as well as open-label comparative studies. These study designs were used in research exploring how symptoms change over time in patients experiencing acute, uncomplicated diarrheal episodes. Researchers in these trials systematically measured outcomes related to episodic or acute changes, such as the duration of diarrheal episodes, the monitoring of stool frequency, and objective measures of stool consistency.

Research describes that the two components of Cortafan have been individually evaluated in studies. The anti-infective component, Nifuroxazide, was studied in trials exploring conditions characterized by acute or disruptive episodes, and the adsorbent component, Attapulgite, was evaluated in studies examining outcomes related to physical discomfort. This evidence contributes to the broader evidence landscape related to conditions involving periods of heightened symptoms where study outcomes related to systemic or functional imbalance were examined in trials.

Evidence in Special Populations

Research has largely focused on adult patients with acute, self-limiting diarrhea. Research has more limited evidence exploring the anti-infective component within pediatric patient groups diagnosed with acute intestinal infections. This research describes observed short-term changes in these specific groups, but data for certain groups remain insufficient. The evidence available for pediatric populations is more limited compared to that for adults, meaning the results apply only to the populations studied in the trials.

Follow-up Duration and Long-Term Studies

The clinical research conducted for this medicine focuses on the acute nature of the condition it addresses. Consequently, follow-up durations were limited, typically monitoring patient status over defined time intervals that last up to seven days post-treatment. Research highlights that the outcomes measured are exclusively related to episodic or acute changes. Therefore, long-term effects are not fully established, and there is limited information for long-term outcomes regarding the durability of the effect or patterns of fluctuating or unstable symptoms after the defined observation period.

What is Still Uncertain About Cortafan

Current research contributes to understanding symptom patterns but also highlights several areas where more information is needed. The evidence quality may vary across studies. A significant portion of the most reported data evaluates the active components separately rather than the combined fixed-dose product, meaning comparative evidence for the exact combination is lacking. Findings describe group patterns, not personal outcomes, and the evidence highlights what is known — and what is still uncertain regarding its role in managing conditions presenting with acute or disruptive episodes.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Cortafan (FAQ)

Q: How quickly does Cortafan typically start to work?

Official information indicates that Cortafan is designed for a prompt, localized effect strictly within the digestive tract. Its active components work in the gut lumen, which is the site of the acute symptoms. Since the drug is non-systemic and does not rely on absorption into the bloodstream, the intended therapeutic effect is targeted quickly to the site of action.

Q: What should I do if I feel like Cortafan is not helping?

Regulatory documents define a mandated short duration of use for this medicine, typically limited to three days. Official guidelines describe that if no improvement in symptoms is seen within this specific timeframe, discontinuation of the medicine may be considered. Information emphasizes the importance of consulting a qualified healthcare professional for further evaluation.

Q: Are headaches a common concern reported with Cortafan?

Regulatory safety data classifies headache as a less common concern reported by users of the anti-infective component in Cortafan. The most frequent adverse effects generally relate to the digestive system and immune reactions. It is generally advisable to communicate any adverse reaction to a healthcare professional.

Q: Is it okay to use cold and flu medicine while taking Cortafan?

Cortafan’s adsorbent component can physically bind to and reduce the absorption of other orally administered medicinal products. Therefore, the official label requires a mandatory timing separation for cold and flu medicine and any other oral substance. This separation is typically required to be at least two to three hours before or after taking Cortafan.

Q: What foods or drinks should people pay attention to when using Cortafan?

According to the official administration instructions, Cortafan is generally intended to be taken with meals or food. Regulatory caution notes that maintaining adequate hydration is relevant while using the medicine. This is because the adsorbent component may contribute to dehydration if sufficient water is not consumed.

Q: Can Cortafan be used by older adults?

Regulatory eligibility documents permit the use of Cortafan in older adults, but they advise caution in this population. The physical binding mechanism of the medicine's adsorbent component is described as potentially increasing the risk of physical consequences, such as impaction, in older or debilitated patients.

Q: How long does Cortafan stay in the body after the last use?

Official information states that Cortafan is non-systemic, meaning its action is highly localized to the intestinal lumen. The active substances have negligible absorption into the bloodstream. Because of this design, unchanged drug is typically not detectable in the human blood or urine after use.

Q: What are the most common reasons someone might stop using Cortafan?

Regulatory pharmacovigilance reports indicate that the most frequent documented reasons for treatment cessation relate to two main groups of adverse reactions. These groups include skin and immune system disorders (such as rash or swelling) and common gastrointestinal disturbances like nausea, vomiting, or increased constipation.

Q: Why do official documents mention the possibility of liver changes with Cortafan?

Regulatory guidelines label the medicine for use with caution in individuals who have compromised hepatic (liver) function. This is a standard precautionary measure applied when full safety and pharmacokinetic data for the product are limited in patients with reduced organ function.

Q: Does taking Cortafan with food change how it works?

The official administration guidelines require the medicine to be taken with food or meals. This regulatory condition is put in place to ensure the correct environment and conditions for the intended effect of the medicine.

Q: Are there different versions or strengths of Cortafan?

Official documentation confirms that Cortafan is available in two different physical formulations: an oral capsule and a liquid oral suspension. Both formulations contain a fixed unit dose and are prescribed for the same short duration of use.

Q: Does Cortafan have a warning about driving or operating machinery?

Regulatory safety profiles list dizziness and general malaise (discomfort) as reported adverse reactions. Due to the possibility of impairment, official caution describes that affected individuals should take appropriate measures.

Q: Does Cortafan affect birth control pills?

The medicine's adsorbent component can potentially reduce the absorption of all other orally administered medicines, which includes oral contraceptives. Mandatory timing separation is required for the use of Cortafan with any other oral medicine to minimize the risk of a potential reduction in the other drug's efficacy.

Q: Does Cortafan affect sugar levels in people with diabetes?

Regulatory guidance specifically includes a caution for individuals with diabetes when considering the use of Cortafan. This indicates that professional monitoring or careful consideration of this population may be necessary during the mandated short course of treatment.

Q: Is Cortafan approved for use in countries outside of the US?

Yes, the anti-infective component is listed under the global classification system maintained by the World Health Organization (WHO). Its use and regulation are covered by international pharmacovigilance reports, confirming its use in numerous countries internationally.

Q: Why do some people say Cortafan made them feel dizzy?

Regulatory safety profiles and pharmacovigilance reports document the possibility of dizziness as a reported adverse reaction. This reaction is generally classified under central nervous system effects or general disorders.

Q: What if I have an existing stomach condition, is Cortafan still appropriate?

Official eligibility rules strictly contraindicate Cortafan for individuals with known or suspected intestinal obstruction, impaction, or severe constipation. For other non-obstructive stomach conditions, evaluation by a healthcare professional is necessary to determine the appropriateness of the short-term medicine.

How should Cortafan be stored and disposed of?

How to Store and Dispose of Cortafan?

The official storage and disposal requirements for Cortafan are defined by governmental regulatory documents to maintain product integrity and ensure safety.

Storage Requirements

Requirement	Official Mandate
Temperature	Store at controlled room temperature (e.g., 15 C to 30 C); Do not freeze
Protection	Keep in the original, tightly closed container; Protect from excessive heat, moisture, and light
Stability Limit	The Oral Suspension must be discarded after 7 days following reconstitution
Safety	Keep out of the sight and reach of children

Disposal Instructions

Unused or expired medicine must be disposed of in accordance with local, regional, or national regulations. It is strictly prohibited to throw the product away via wastewater or household waste.

Cortafan